A digital view of the world illustrates how Astellas is a global company committed to serving patients worldwide.

News

Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.

XTANDI™▼ (ENZALUTAMIDE) AUTHORISED IN THE EUROPEAN UNION (EU) FOR ADVANCED PROSTATE CANCER
Jun 24, 2013
Enzalutamide authorised in European Union (EU) for the treatment of adult men with metastatic castration-resistant prostate cancer whose disease has progressed on or after docetaxel therapy1